Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of America's Car-Mart, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Legal Action and Investor Rights - Investors who purchased America's Car-Mart securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Company Performance and Market Reaction - On September 4, 2025, America's Car-Mart reported a first-quarter loss of 69 cents per share, compared to a net loss of 15 cents per share in the same period the previous year [3]. - Following the release of these results, America's Car-Mart's stock experienced a significant decline of 18.2% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4].

Core Viewpoint - A class action lawsuit has been filed against DeFi Technologies, Inc. for misleading statements regarding its financial performance and business operations during the specified Class Period from May 12, 2025, to November 14, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that DeFi Technologies made false and misleading statements about delays in executing its DeFi arbitrage strategy, which is a key revenue driver [5]. - It is alleged that the company understated the competition it faced from other digital asset treasury companies, impacting its ability to execute its strategy [5]. - The lawsuit asserts that DeFi Technologies was unlikely to meet its previously issued revenue guidance for the fiscal year 2025 due to these issues [5]. Group 2: Investor Information - Investors who purchased DeFi Technologies securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Freeport-McMoRan Inc. securities between February 15, 2022, and September 24, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Freeport-McMoRan securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 12, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Freeport-McMoRan made false and misleading statements regarding safety measures at the Grasberg Block Cave mine in Indonesia, which posed a heightened risk to workers [5]. - It is claimed that the lack of proper safety precautions led to undisclosed regulatory, litigation, and reputational risks, resulting in materially false statements about the company's business and operations [5].

Core Viewpoint - A class action lawsuit has been initiated against Blue Owl Capital Inc. for alleged misleading statements and undisclosed liquidity issues affecting its business operations during the specified period [2][6]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between February 6, 2025, and November 16, 2025 [2]. - Allegations include that Blue Owl faced significant pressure on its asset base due to business development companies (BDC) redemptions, leading to undisclosed liquidity issues [6]. - The lawsuit claims that the defendants downplayed the severity of these issues, resulting in materially misleading statements about Blue Owl's business prospects [6]. Group 2: Investor Actions - Investors who purchased or sold Blue Owl securities during the class period may be entitled to compensation without upfront costs through a contingency fee arrangement [3]. - Interested investors can join the class action by submitting a form or contacting the law firm directly [4][7]. - A lead plaintiff must be appointed by February 2, 2026, to represent the class in the litigation [2][4]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [5]. - The firm emphasizes the importance of selecting qualified legal counsel with proven success in similar cases [5].

Core Points - Rosen Law Firm has announced a class action lawsuit on behalf of investors of Sprouts Farmers Market, Inc. for the period between June 4, 2025, and October 29, 2025, with a deadline for lead plaintiff applications set for January 26, 2026 [2][4] Group 1: Class Action Details - Investors who purchased Sprouts Farmers Market securities or sold put options during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3] - The lawsuit alleges that the defendants provided misleading information regarding Sprouts Farmers Market's growth potential, claiming resilience against macroeconomic pressures while concealing adverse facts that indicated a potential slowdown in sales growth [6] Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their past successes and recognition in the field [5] - Investors are encouraged to join the class action by contacting the firm directly for more information [4][7]

Core Points - Rosen Law Firm is reminding investors who purchased Perrigo Company plc securities between February 27, 2023, and November 4, 2025, of the January 16, 2026, lead plaintiff deadline for a class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Company Details - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business acquired from Nestlé, including significant underinvestment in maintenance and the need for substantial capital expenditures [4] - The lawsuit claims that Perrigo's financial results, including earnings and cash flow, were overstated due to these issues, leading to misleading positive statements about the company's business and prospects [4] Legal Process - To join the class action, investors can submit a form or contact the law firm directly, with a lead plaintiff needing to move the court by January 16, 2026 [2][5] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Alvotech due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a press release from Alvotech on November 2, 2025, which announced that the U.S. FDA issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, indicating deficiencies that must be resolved before approval [3]. - Following the announcement of the CRL, Alvotech's stock price experienced a significant decline, falling 34% on November 3, 2025, and nearly 4% on November 4, 2025 [3]. Group 2: Class Action Information - Shareholders who purchased Alvotech securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - Interested investors can join the prospective class action by visiting the provided link or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and consistently ranking among the top firms for securities class action settlements since 2013 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Performance and Issues - On August 4, 2025, Agilon Health reported its second quarter results, indicating that industry headwinds were more severe than previously anticipated, leading to the suspension of its full-year 2025 financial guidance [3]. - Following the announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025 [3]. Group 2: Legal Actions and Investor Rights - Investors who purchased Agilon Health securities may be eligible for compensation through a class action lawsuit without any out-of-pocket fees, as the Rosen Law Firm is preparing to seek recovery of investor losses [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering substantial amounts for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Synopsys, Inc. securities between December 4, 2024, and September 9, 2025, of the December 30, 2025, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Synopsys securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is December 30, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that Synopsys' management made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [5]. - Specific allegations include the negative impact of Synopsys' focus on artificial intelligence customers on its Design IP business and the misleading nature of positive statements made by the defendants regarding the company's prospects [5].

Core Viewpoint - A class action lawsuit has been filed against Blue Owl Capital for failing to disclose significant liquidity issues and pressures on its asset base due to BDC redemptions during the specified class period [2][6]. Financial Performance - Blue Owl reported third-quarter financial results on October 30, 2025, with new capital commitments of $14 billion for the quarter and $57 billion over the last twelve months. Direct lending originations were $10.9 billion for the quarter and $46.8 billion over the last twelve months. However, fee-related earnings were only $376.2 million, missing consensus estimates, and performance revenue fell 33% year over year to $188,000 [3]. - Following the financial report, Blue Owl's share price dropped by $0.70, or approximately 4.23%, from $16.56 to $15.86 [3]. Merger Announcement - On November 5, 2025, Blue Owl Capital Corporation and Blue Owl Capital Corporation II announced a definitive merger agreement, stating that the merger would enhance liquidity for shareholders. The exchange ratio for shares will be based on the NAV per share and market price prior to the merger [4]. - The announcement led to a decline in Blue Owl's share price by $0.74, or approximately 4.72%, from $15.69 to $14.95 [4]. Redemption Issues - A Financial Times article on November 16, 2025, reported that Blue Owl had blocked redemptions in one of its private credit funds, potentially leading to significant losses for investors. Investors in OBCD II will lose the ability to redeem cash at the fund's NAV after the merger, trading their shares for Blue Owl Capital Corporation shares, which are trading about 20% below the fund's NAV [5]. - This news caused Blue Owl's share price to decline by $0.85, or approximately 5.8%, from $14.62 to $13.77 [5].